What's in Tanabe Pharma Corporation's pipeline?

Tanabe Pharma Corporation has 72 drugs in our index: 7 marketed, 0 filed, 31 in Phase 3, 22 in Phase 2, 11 in Phase 1.

Which companies overlap with Tanabe Pharma Corporation's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Sanofi, GlaxoSmithKline, Novartis, Bayer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tanabe-pharma-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Tanabe Pharma Corporation — Portfolio Competitive Intelligence Brief

Tanabe Pharma Corporation pipeline: 7 marketed, 0 filed, 31 Phase 3, 22 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 31 Phase 3 22 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Canagliflozin (TA-7284)	Canagliflozin (TA-7284)	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)	Diabetes
Iron supplement A	Iron supplement A	marketed	Iron supplement	Iron (Fe2+/Fe3+)	Hematology
alpha-glucosidase inhibitor	alpha-glucosidase inhibitor	marketed	Alpha-glucosidase inhibitor	Alpha-glucosidase enzymes (intestinal brush border)	Diabetes
Teneli (Teneligliptin)	Teneli (Teneligliptin)	marketed	DPP-4 inhibitor	DPP-4 (Dipeptidyl peptidase-4)	Diabetes
Iron supplement C	Iron supplement C	marketed	Iron supplement	Iron (Fe2+/Fe3+)	Hematology
GLP-1 analogue	GLP-1 analogue	marketed
Sodium Ozagrel	Sodium Ozagrel	marketed	Thromboxane A2 synthetase inhibitor	Thromboxane A2 synthetase	Cardiovascular
IFN beta(24 weeks)	IFN beta(24 weeks)	phase 3	Interferon	Interferon-alpha/beta receptor (IFNAR)	Immunology
DPT-IPV-Hib (Combined Vaccine)	DPT-IPV-Hib (Combined Vaccine)	phase 3	Pentavalent inactivated vaccine		Immunology / Infectious Disease Prevention
TA-7284 Low	TA-7284 Low	phase 3	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)	Diabetes
DPT-IPV	DPT-IPV	phase 3	Combination vaccine		Immunology / Infectious Disease
MCI-186	MCI-186	phase 3	Free radical scavenger; antioxidant	Reactive oxygen species (ROS); hydroxyl radicals; peroxynitrite	Neurology

Therapeutic area mix

Diabetes · 9
Neurology · 4
Hematology · 4
Immunology · 3
Cardiovascular · 3
Immunology / Infectious Disease Prevention · 3
Immunology / Infectious Disease · 2
Other · 1
Virology/Hepatology · 1
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 7 shared drug classes
Sanofi · 7 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Novartis · 3 shared drug classes
Bayer · 3 shared drug classes
Ain Shams University · 3 shared drug classes
Daewoong Pharmaceutical Co. LTD. · 3 shared drug classes
EMS · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Tanabe Pharma Corporation:

Cite this brief

Drug Landscape (2026). Tanabe Pharma Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tanabe-pharma-corporation. Accessed 2026-05-16.